Editing Potentially Actionable Research
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
The edit can be undone.
Please check the comparison below to verify that this is what you want to do, and then save the changes below to finish undoing the edit.
| Latest revision | Your text | ||
| Line 9: | Line 9: | ||
| Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. {{#pmid:24667005|Boll2014}} || Lithium administered together with valproate prolonged patient survival in a statistically limited study. || Discuss with your neurologist about the possibility of trying the said combination. The dosage used in the referred study was 300 mg of each drug three times a day. | | Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. {{#pmid:24667005|Boll2014}} || Lithium administered together with valproate prolonged patient survival in a statistically limited study. || Discuss with your neurologist about the possibility of trying the said combination. The dosage used in the referred study was 300 mg of each drug three times a day. | ||
|- | |- | ||
| − | |Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. {{#pmid:23421600|Beghi2013}}|| | + | |Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. {{#pmid:23421600|Beghi2013}}||ALCAR showed signs of efficacy in a statistically limited trial. || Consider ALCAR supplementation. |
|} | |} | ||
